LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Roivant Sciences Ltd

Open

BrancheGesundheitswesen

10.78 0.37

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.64

Max

10.86

Schlüsselkennzahlen

By Trading Economics

Einkommen

212M

25M

Verkäufe

4.5M

9M

EPS

-0.199

Gewinnspanne

280.018

Angestellte

908

EBITDA

-52M

-274M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+68.7% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

7.8B

Vorheriger Eröffnungskurs

10.41

Vorheriger Schlusskurs

10.78

Nachrichtenstimmung

By Acuity

50%

50%

173 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2025, 22:52 UTC

Ergebnisse
Wichtige Markttreiber

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. Mai 2025, 20:37 UTC

Top News
Ergebnisse

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. Mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. Mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. Mai 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. Mai 2025, 22:46 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 21:58 UTC

Ergebnisse

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. Mai 2025, 21:24 UTC

Ergebnisse

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. Mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. Mai 2025, 20:54 UTC

Market Talk
Ergebnisse

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. Mai 2025, 20:54 UTC

Ergebnisse

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. Mai 2025, 20:51 UTC

Ergebnisse

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Mai 2025, 20:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. Mai 2025, 20:50 UTC

Ergebnisse

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. Mai 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. Mai 2025, 20:25 UTC

Ergebnisse

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer-Vergleich

Kursveränderung

Roivant Sciences Ltd Prognose

Kursziel

By TipRanks

68.7% Vorteil

12-Monats-Prognose

Durchschnitt 18 USD  68.7%

Hoch 18 USD

Tief 18 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Roivant Sciences Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

11 / 11.18Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

173 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.